Home LiteratureArticle Details
PMID: 19443538 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Mechanisms of bone metastases of breast cancer.

Endocrine-related cancer ·Vol. 16 ·No. 3 ·2009-09-00 ·Pages 703-13

Suva LJ, Griffin RJ, Makhoul I

Abstract

Cancer development is a multi-step process driven by genetic alterations that elicit the progressive transformation of normal human cells into highly malignant derivatives. The altered cell proliferation phenotype of cancer involves a poorly characterized sequence of molecular events, which often result in the development of distant metastasis. In the case of breast cancer, the skeleton is among the most common of metastatic sites. In spite of its clinical importance, the underlying cellular and molecular mechanisms driving bone metastasis remain elusive. Despite advances in our understanding of the phenotype of cancer cells, the increased focus on the contribution of the tumor microenvironment and the recent revival of interest in the role of tumor-propagating cells (so called cancer stem cells) that may originate or be related to normal stem cells produced in the bone marrow, many important questions remain unanswered. As such, a more complete understanding of the influences of both the microenvironment and the tumor phenotype, which impact the entire multi-step metastatic cascade, is required. In this review, the importance of tumor heterogeneity, tumor-propagating cells, the microenvironment of breast cancer metastasis to bone as well as many current endocrine therapies for the prevention and treatment of metastatic breast cancer is discussed.

MeSH Terms
Bone Neoplasms/diagnosis,genetics,secondary,therapy Breast Neoplasms/diagnosis,genetics,pathology,therapy Cell Transformation, Neoplastic/genetics,pathology Female Humans Models, Biological Prognosis Recurrence Signal Transduction/genetics
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Suva Larry J
Department of Orthopaedic Surgery, Barton Research Institute, Center for Orthopaedic Research, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA. suvalarryj@uams.edu
Griffin Robert J
Makhoul Issam
References (80)
80 references, click to expand
  1. Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases.
    Cancer Res. 2005 Jul 1;65(13):5778-84 PMID: 15994953
  2. Expression of a calcium-mobilizing parathyroid hormone-like peptide in lactating mammary tissue.
    Science. 1988 Oct 14;242(4876):278-80 PMID: 3175653
  3. CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract.
    Mol Reprod Dev. 1997 Jan;46(1):71-4 PMID: 8981366
  4. Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients.
    Breast Cancer Res Treat. 1998 Jun;49(3):195-208 PMID: 9776503
  5. Parathyroid hormone-related protein localization in breast cancers predict improved prognosis.
    Cancer Res. 2006 Feb 15;66(4):2250-6 PMID: 16489028
  6. Validation of 70-gene prognosis signature in node-negative breast cancer.
    Breast Cancer Res Treat. 2009 Oct;117(3):483-95 PMID: 18819002
  7. Clinical features of metastatic bone disease and risk of skeletal morbidity.
    Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6243s-6249s PMID: 17062708
  8. Risks and benefits of bisphosphonates.
    Br J Cancer. 2008 Jun 3;98(11):1736-40 PMID: 18506174
  9. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression.
    Science. 1987 Aug 21;237(4817):893-6 PMID: 3616618
  10. The epithelial-mesenchymal transition generates cells with properties of stem cells.
    Cell. 2008 May 16;133(4):704-15 PMID: 18485877
  11. Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. The Breast Cancer Study Group.
    Breast Cancer Res Treat. 1991 Mar;18(1):27-32 PMID: 1854977
  12. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent.
    Cancer Cell. 2005 May;7(5):411-23 PMID: 15894262
  13. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
    Lancet. 2007 Feb 17;369(9561):559-70 PMID: 17307102
  14. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.
    J Natl Cancer Inst. 2007 Nov 21;99(22):1683-94 PMID: 18000219
  15. Circulating colony stimulating factor-1 and breast cancer risk.
    Cancer Res. 2008 Jan 1;68(1):18-21 PMID: 18172291
  16. Genes associated with breast cancer metastatic to bone.
    J Clin Oncol. 2006 May 20;24(15):2261-7 PMID: 16636340
  17. A cytokine-mediated link between innate immunity, inflammation, and cancer.
    J Clin Invest. 2007 May;117(5):1175-83 PMID: 17476347
  18. Proteomic analysis of bone cancer: a review of current and future developments.
    Expert Rev Proteomics. 2007 Jun;4(3):371-8 PMID: 17552921
  19. Is tumor growth sustained by rare cancer stem cells or dominant clones?
    Cancer Res. 2008 Jun 1;68(11):4018-21 PMID: 18519656
  20. Percutaneous combined therapy for painful sternal metastases: a radiofrequency thermal ablation (RFTA) and cementoplasty protocol.
    Anticancer Res. 2007 Nov-Dec;27(6C):4259-62 PMID: 18214029
  21. Repeated observation of breast tumor subtypes in independent gene expression data sets.
    Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 PMID: 12829800
  22. Oncogenic pathway signatures in human cancers as a guide to targeted therapies.
    Nature. 2006 Jan 19;439(7074):353-7 PMID: 16273092
  23. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways.
    Cancer Res. 2008 May 15;68(10):3645-54 PMID: 18483246
  24. Breast cancer metastasis to bone: it is not all about PTHrP.
    Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S39-45 PMID: 14600591
  25. Clonal selection of metastasis within the life history of a tumor.
    Cancer Res. 2007 Dec 15;67(24):11471-5 PMID: 18089772
  26. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited.
    Nat Rev Cancer. 2003 Jun;3(6):453-8 PMID: 12778135
  27. Biological functions and clinical implications of oestrogen receptors alfa and beta in epithelial tissues.
    J Intern Med. 2008 Aug;264(2):128-42 PMID: 18513343
  28. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
    J Clin Oncol. 2008 Oct 20;26(30):4875-82 PMID: 18725648
  29. Road map to metastasis.
    Nat Med. 2003 Aug;9(8):999-1000 PMID: 12894162
  30. Clinical course and prognostic factors following bone recurrence from breast cancer.
    Br J Cancer. 1998;77(2):336-40 PMID: 9461007
  31. Tumor growth need not be driven by rare cancer stem cells.
    Science. 2007 Jul 20;317(5836):337 PMID: 17641192
  32. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer.
    J Clin Invest. 2004 Dec;114(12):1714-25 PMID: 15599396
  33. Beyond tumorigenesis: cancer stem cells in metastasis.
    Cell Res. 2007 Jan;17(1):3-14 PMID: 17179981
  34. Genomics and proteomics of bone cancer.
    Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6217s-6221s PMID: 17062704
  35. The distribution of secondary growths in cancer of the breast. 1889.
    Cancer Metastasis Rev. 1989 Aug;8(2):98-101 PMID: 2673568
  36. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.
    J Clin Oncol. 2007 Oct 1;25(28):4431-7 PMID: 17785705
  37. Ductal carcinoma in situ, complexities and challenges.
    J Natl Cancer Inst. 2004 Jun 16;96(12):906-20 PMID: 15199110
  38. [Monoclonal antibody targeting RANKL as a therapy for cancer-induced bone diseases].
    Clin Calcium. 2006 Apr;16(4):627- 35 PMID: 16582514
  39. Breast cancer metastasis: markers and models.
    Nat Rev Cancer. 2005 Aug;5(8):591-602 PMID: 16056258
  40. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
    Lancet Oncol. 2008 Jan;9(1):45-53 PMID: 18083636
  41. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups.
    JAMA. 2007 Dec 26;298(24):2869-76 PMID: 18159056
  42. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Lancet Oncol. 2008 Sep;9(9):840-9 PMID: 18718815
  43. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.
    Lancet. 2005 Feb 19-25;365(9460):671-9 PMID: 15721472
  44. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone.
    Hum Pathol. 2003 Jul;34(7):646-53 PMID: 12874759
  45. Percutaneous minimally invasive therapies in the treatment of bone tumors: thermal ablation.
    Semin Musculoskelet Radiol. 2006 Jun;10(2):137-44 PMID: 16598666
  46. Identification of the breast cancer susceptibility gene BRCA2.
    Nature. 1995 Dec 21-28;378(6559):789-92 PMID: 8524414
  47. Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer.
    Br J Cancer. 2007 Sep 3;97(5):646-53 PMID: 17687336
  48. BRCA1 regulates human mammary stem/progenitor cell fate.
    Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1680-5 PMID: 18230721
  49. Overexpression of parathyroid hormone-related protein or parathyroid hormone in transgenic mice impairs branching morphogenesis during mammary gland development.
    Development. 1995 Nov;121(11):3539-47 PMID: 8582268
  50. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy.
    Cancer Res. 2005 Dec 1;65(23):10692-9 PMID: 16322213
  51. Bone metastases from breast carcinoma: histopathological - radiological correlations and prognostic features.
    Br J Cancer. 2003 Aug 18;89(4):660-5 PMID: 12915874
  52. Inflammation and cancer.
    Nature. 2002 Dec 19-26;420(6917):860-7 PMID: 12490959
  53. Sorting out breast-cancer gene signatures.
    N Engl J Med. 2007 Jan 18;356(3):294-7 PMID: 17229957
  54. The importance of distant metastases in hormone-sensitive breast cancer.
    Breast. 2008 Jan;17 Suppl 1:S3-8 PMID: 18279764
  55. Differential expression of hypoxia and (lymph)angiogenesis-related genes at different metastatic sites in breast cancer.
    Clin Exp Metastasis. 2007;24(1):13-23 PMID: 17295094
  56. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity.
    Blood. 2000 Sep 1;96(5):1953-60 PMID: 10961900
  57. Treatment of breast cancer with bone metastasis: bisphosphonate treatment - current and future.
    Int J Clin Oncol. 2008 Feb;13(1):18-23 PMID: 18307015
  58. A multigenic program mediating breast cancer metastasis to bone.
    Cancer Cell. 2003 Jun;3(6):537-49 PMID: 12842083
  59. Microenvironmental and cellular consequences of altered blood flow in tumours.
    Br J Radiol. 2003;76 Spec No 1:S11-22 PMID: 15456710
  60. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.
    Breast Cancer Res Treat. 2002 Nov;76(1):27-36 PMID: 12408373
  61. Radiotherapy for palliation of symptoms in incurable cancer.
    Curr Probl Cancer. 1997 May-Jun;21(3):129-83 PMID: 9202888
  62. Platelet glycoprotein Ib alpha supports experimental lung metastasis.
    Proc Natl Acad Sci U S A. 2007 May 22;104(21):9024-8 PMID: 17494758
  63. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
    Cancer Res. 2005 Dec 1;65(23):11001-9 PMID: 16322249
  64. Metastasis to bone: causes, consequences and therapeutic opportunities.
    Nat Rev Cancer. 2002 Aug;2(8):584-93 PMID: 12154351
  65. Detection of transcripts for the receptor for macrophage colony-stimulating factor, c-fms, in murine osteoclasts.
    Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9637-41 PMID: 1409676
  66. The management of asymptomatic skeletal breast cancer: a paradigm shift.
    Ann Surg Oncol. 2007 Sep;14(9):2430-1 PMID: 17562111
  67. Angiogenesis in the bone marrow of patients with breast cancer.
    Clin Cancer Res. 2005 Aug 1;11(15):5396-400 PMID: 16061853
  68. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
    Science. 1994 Oct 7;266(5182):66-71 PMID: 7545954
  69. A gene-expression signature as a predictor of survival in breast cancer.
    N Engl J Med. 2002 Dec 19;347(25):1999-2009 PMID: 12490681
  70. Metastatic carcinoma of the long bones.
    Am Fam Physician. 2007 Nov 15;76(10):1489-94 PMID: 18052014
  71. Overexpression of parathyroid hormone-related protein causes hypercalcemia but not bone metastases in a murine model of mammary tumorigenesis.
    J Bone Miner Res. 2002 Jul;17(7):1164-70 PMID: 12096830
  72. The pathogenesis of cancer metastasis.
    Nature. 1980 Jan 10;283(5743):139-46 PMID: 6985715
  73. The bone microenvironment in metastasis; what is special about bone?
    Cancer Metastasis Rev. 2008 Mar;27(1):41-55 PMID: 18071636
  74. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    J Clin Oncol. 2007 Feb 10;25(5):486-92 PMID: 17200148
  75. The clinical course of bone metastases from breast cancer.
    Br J Cancer. 1987 Jan;55(1):61-6 PMID: 3814476
  76. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption.
    Cancer Res. 2007 Apr 15;67(8):3646-53 PMID: 17440076
  77. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis.
    Breast Cancer Res Treat. 2000 Feb;59(3):271-8 PMID: 10832597
  78. The genomic landscapes of human breast and colorectal cancers.
    Science. 2007 Nov 16;318(5853):1108-13 PMID: 17932254
  79. Cancer metastasis: building a framework.
    Cell. 2006 Nov 17;127(4):679-95 PMID: 17110329
  80. Is cancer a disease of self-seeding?
    Nat Med. 2006 Aug;12(8):875-8 PMID: 16892025
Article Info
Journal
Endocrine-related cancer
Abbr.
Endocr Relat Cancer
ISSN
1479-6821
Published
2009-09-00
Epub
2009-00-14
Pages
703-13
Language
English
Region
England
NLM ID
9436481
PMCID
PMC2914697
Subset
IM
Grants
NCI NIH HHS · R01 CA107160 · United States
NCI NIH HHS · R01 CA107160-04 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com